lundi 2 juillet 2018

Onco Actu du 2 juillet 2018

2. Etiologie

Study Links Time Spent Sitting to Higher Risk of Death from 14 Diseases [ACS]

3.1 Prévention - Tabac

As Australia wins another challenge to tobacco plain packaging, that sound you hear is the dominoes toppling [Croakey]

5. Traitements

NExT: Advancing Promising Cancer Therapies from the Lab to Clinical Trials [NCI]

5.12 Immunothérapies

Immunotherapy: hype and hope [Lancet Oncology]

5.12.2 Immunothérapies - CAR-T, thérapies cellulaires

European CHMP Adopts Positive Opinion for Yescarta® (axicabtagene ciloleucel) for the Treatment of Relapsed or Refractory DLBCL and PMBCL, After Two or More Lines of Systemic Therapy [Gilead]

CAR-T race heads to Europe as Gilead, Novartis drugs score CHMP backing [FiercePharma]

Novartis receives positive CHMP opinion for Kymriah® for treating two aggressive blood cancers, marking important medical advance for patients in Europe [Novartis]

CAR-T Immunotherapies May Have a New Player [UC San Diego]

Rival Novartis, Gilead CAR-T therapies win European panel recommendation [Reuters]

First two CAR-T cell medicines recommended for approval in the European Union [EMA]

5.12.3 Immunothérapies-combinaisons

Roche 'highly encouraged' by Tecentriq results in breast cancer

Phase III IMpassion130 study showed Roche’s Tecentriq plus Abraxane significantly reduced the risk of disease worsening or death in people with metastatic triple negative breast cancer [Roche]

5.12.6 Immunothérapies - AMM

Bristol-Myers Squibb Receives Positive CHMP Opinion Recommending Approval of Opdivo (nivolumab) for the Adjuvant Treatment of Adult Patients with Melanoma [BMS]

Imfinzi approved in Japan for unresectable Stage III non-small cell lung cancer [AstraZeneca]

AstraZeneca wins speedy approvals for cancer drugs in Japan [Reuters]

5.3.4 Traitements - AMM (FDA, EMA,...)

Lynparza approved in Japan for BRCA-mutated metastatic breast cancer [AstraZeneca]

Puma Biotechnology Receives Positive CHMP Opinion Recommending Approval of NERLYNX® for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer [Puma]

Puma Biotech gets EU panel nod for breast cancer drug [Reuters]

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-28 June 2018 [EMA]

6.6 Publications

35,000 papers may need to be retracted for image doctoring, says new paper [Retraction Watch]

6.7.2 Applis

Why telemedicine has been such a bust so far [CNBC]

6.9 Controverses

Irish woman receives €7.4m over cervical smear cancer scandal [The Guardian]